Last reviewed · How we verify
Selinexor Tablets
Selinexor is a selective inhibitor of nuclear export (SINE) that blocks XPO1/CRM1, preventing the export of tumor suppressor proteins from the nucleus and leading to their accumulation and activation.
Selinexor is a selective inhibitor of nuclear export (SINE) that blocks XPO1/CRM1, preventing the export of tumor suppressor proteins from the nucleus and leading to their accumulation and activation. Used for Multiple myeloma (in combination with dexamethasone), Diffuse large B-cell lymphoma (DLBCL), Acute myeloid leukemia (AML).
At a glance
| Generic name | Selinexor Tablets |
|---|---|
| Sponsor | Chengdu Zenitar Biomedical Technology Co., Ltd |
| Drug class | Selective inhibitor of nuclear export (SINE) |
| Target | XPO1/CRM1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Selinexor selectively inhibits exportin 1 (XPO1/CRM1), a nuclear export protein responsible for transporting various cargo proteins including tumor suppressors out of the nucleus. By blocking this export, selinexor causes accumulation of tumor suppressors like p53, IκB, and PTEN in the nucleus, restoring their anti-cancer functions. This mechanism is particularly effective in hematologic malignancies and certain solid tumors where XPO1 is often overexpressed.
Approved indications
- Multiple myeloma (in combination with dexamethasone)
- Diffuse large B-cell lymphoma (DLBCL)
- Acute myeloid leukemia (AML)
Common side effects
- Nausea
- Fatigue
- Diarrhea
- Thrombocytopenia
- Anemia
- Vomiting
- Neutropenia
- Hyponatremia
Key clinical trials
- Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma (PHASE3)
- Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma (PHASE2)
- Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (PHASE2)
- Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial) (PHASE2)
- A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia (PHASE2)
- Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma (PHASE3)
- A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM. (PHASE2)
- NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Selinexor Tablets CI brief — competitive landscape report
- Selinexor Tablets updates RSS · CI watch RSS
- Chengdu Zenitar Biomedical Technology Co., Ltd portfolio CI